Chemotherapy and radiation not only trigger cancer cell apoptosis but also damage stromal
cells in the tumour microenvironment (TME), inducing a senescence-associated secretory …

Secretory factors that drive cancer progression are attractive immunotherapeutic targets. We
used a whole‐genome data‐mining approach on multiple cohorts of breast tumours …

Serine Peptidase Inhibitor Kazal Type 1 (SPINK1) is a secreted protein known as a protease
inhibitor of trypsin in the pancreas. However, emerging evidence shows its function in …

Colorectal cancer (CRC) is the third most common cancer in the world, and second leading
cause of cancer deaths in the US. Although, anti-EGFR therapy is commonly prescribed for …

Hypoxia is associated with tumor radioresistance; therefore, a predictive marker for tumor
hypoxia and a rational target to overcome it have been sought to realize personalized …

BACKGROUND Tumor-associated trypsin inhibitor (TATI) was originally isolated from the
urine of a patient with ovarian cancer. It was later shown to be produced by many other …

Purpose: Evasion from chemotherapy-induced apoptosis due to p53 loss strongly
contributes to drug resistance. Identification of specific targets for the treatment of drug …

Serine protease inhibitor Kazal type 1 (SPINK1) plays a role in protecting the pancreas
against premature activation of trypsinogen and is involved in cancer progression. SPINK1 …

Background SPINK4 is known as a gastrointestinal peptide in the gastrointestinal tract and is
abundantly expressed in human goblet cells. The clinical significance of SPINK4 in …

Abstract Background Serine protease inhibitor Kazal type I (SPINK1) is highly expressed
and promotes tumor progress in different cancers. This study aimed to evaluate SPINK1's …